Oncolytics Biotech Files 6-K

Ticker: ONCY · Form: 6-K · Filed: Oct 28, 2025 · CIK: 1129928

Sentiment: neutral

Topics: reporting, foreign-private-issuer, administrative

Related Tickers: ONC

TL;DR

ONCOLYTICS BIOTECH (ONC) filed a 6-K, confirming US address and 20-F filing for annual reports.

AI Summary

Oncolytics Biotech Inc. filed a Form 6-K on October 28, 2025, reporting as a foreign private issuer. The filing indicates the company's principal executive offices are located at 4350 Executive Drive, Suite 325, San Diego, CA 92121, and that it files annual reports under Form 20-F.

Why It Matters

This filing provides an update on Oncolytics Biotech Inc.'s reporting status and administrative information as a foreign private issuer.

Risk Assessment

Risk Level: low — This is a routine administrative filing and does not contain new material financial or operational information.

Key Players & Entities

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of foreign private issuers required to be filed pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, typically to provide information that the registrant makes or is required to make public pursuant to the laws of its home country, or that it furnishes or is required to furnish to its security holders.

What does it mean that Oncolytics Biotech Inc. is a 'foreign private issuer'?

A 'foreign private issuer' is a foreign entity that is not a U.S. person and meets certain other criteria, allowing it to file under different SEC rules than domestic U.S. companies.

Which form does Oncolytics Biotech Inc. use for its annual reports?

Oncolytics Biotech Inc. files its annual reports under cover of Form 20-F.

Where are Oncolytics Biotech Inc.'s principal executive offices located?

The principal executive offices of Oncolytics Biotech Inc. are located at 4350 Executive Drive, Suite 325, San Diego, CA 92121.

What is the filing date of this Form 6-K?

This Form 6-K was filed as of October 28, 2025.

Filing Stats: 332 words · 1 min read · ~1 pages · Grade level 17 · Accepted 2025-10-28 07:43:26

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Oncolytics Biotech Inc. (Registrant) By s Kirk Look Date October 28, 2025 Kirk Look Chief Financial Officer

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing